Global Blood Screening

Blood Screening Comprehensive Study by Type (Reagents & Kits, Instruments, Software & Services), Application (Blood Bank, Hospitals), Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next-Generation Sequencing (NGS), Western Blotting) Players and Region - Global Market Outlook to 2030

Blood Screening Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Blood Screening
The main objective of blood screening is to detect markers of infection so as to prevent the release of infected blood and blood components for clinical use. Blood screening strategies are designed to ensure the safety of blood units, but should not be used for notifying blood donors of reactive test results. The appropriate confirmatory testing policy for blood donor management should be applied before notifying donors of their infectivity status. The screening of donated blood and the quarantine of blood and blood components represent critical processes that should be followed to assure that blood units are safe. Based on the screening results, they should either be released for clinical or manufacturing usage or be discarded.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.2%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Blood Screening market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Grifols (Spain), Bio-Rad Laboratories, Inc. (United States), Roche Diagnostics (Switzerland), BioMérieux (France), Abbott Laboratories (United States), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (United States), Beckman Coulter, Inc. (United States), Ortho Clinical Diagnostics, Inc. (United States) and Becton, Dickinson and Company (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Trinity Biotech (Ireland), Luminex Corp (United States) and Alere Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Blood Screening market by Type (Reagents & Kits, Instruments and Software & Services), Application (Blood Bank and Hospitals) and Region.



On the basis of geography, the market of Blood Screening has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Spain, Italy, Ireland, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Nucleic Acid Amplification Test (NAT) will boost the Blood Screening market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Blood Screening Methods

Market Growth Drivers:
Growing Prevalence of Infectious Diseases and Increasing Demand for Donated Blood

Challenges:
Introduction of Alternative Technologies

Restraints:
Lack of Skilled Manpower

Opportunities:
Improving Health Care Infrastructure in Developing Countries

Market Leaders and their expansionary development strategies
In November 2023, Universal DX ("UDX"), a biotech company on a mission to transform cancer into a curable disease, today announced a strategic collaboration with Quest Diagnostics ("Quest") (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve colorectal cancer screening
In November 2023, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
The FDA Center for Biologics Evaluation and Research, or CBER, Office of Blood Research and Review, called OBRR, reviews several different types of regulatory applications with respect to blood and blood components. This includes biologics license applications, called BLAs, which represent the regulatory pathway for blood components. The BLA regulatory process also applies to biological drugs such as fractionated plasma products. and OBRR also regulates in-vitro diagnostic devices used for screening of collected blood, and does so also using the BLA regulatory pathway. Review of these devices as biologic licenses allows CBER to apply a higher level of manufacturing oversight, including lot release testing and pre-licensure inspection. This regulatory pathway applies to infectious disease tests for blood screening, as well as blood grouping and phenotyping reagents.

Key Target Audience
Manufacturers of Blood Screening Instruments and Reagents, Software and Services Providers of Blood Screening, Blood Banks, Healthcare industry, Hospitals, Governmental bodies, Regulatory Bodies and Research and Consulting Firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Reagents & Kits
  • Instruments
  • Software & Services
By Application
  • Blood Bank
  • Hospitals
By Technology
  • Nucleic Acid Amplification Test (NAT)
  • ELISA
  • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
  • Next-Generation Sequencing (NGS)
  • Western Blotting

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • Ireland
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Infectious Diseases
      • 3.2.2. Increasing Demand for Donated Blood
    • 3.3. Market Challenges
      • 3.3.1. Introduction of Alternative Technologies
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Blood Screening Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blood Screening, by Type, Application, Technology and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Blood Screening (Value)
      • 5.2.1. Global Blood Screening by: Type (Value)
        • 5.2.1.1. Reagents & Kits
        • 5.2.1.2. Instruments
        • 5.2.1.3. Software & Services
      • 5.2.2. Global Blood Screening by: Application (Value)
        • 5.2.2.1. Blood Bank
        • 5.2.2.2. Hospitals
      • 5.2.3. Global Blood Screening by: Technology (Value)
        • 5.2.3.1. Nucleic Acid Amplification Test (NAT)
        • 5.2.3.2. ELISA
        • 5.2.3.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
        • 5.2.3.4. Next-Generation Sequencing (NGS)
        • 5.2.3.5. Western Blotting
      • 5.2.4. Global Blood Screening Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Spain
          • 5.2.4.3.4. Italy
          • 5.2.4.3.5. Ireland
          • 5.2.4.3.6. United Kingdom
          • 5.2.4.3.7. Netherlands
          • 5.2.4.3.8. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Blood Screening (Price)
      • 5.3.1. Global Blood Screening by: Type (Price)
  • 6. Blood Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Grifols (Spain)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Diagnostics (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioMérieux (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Siemens Healthineers (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Beckman Coulter, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ortho Clinical Diagnostics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Becton, Dickinson and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Blood Screening Sale, by Type, Application, Technology and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Blood Screening (Value)
      • 7.2.1. Global Blood Screening by: Type (Value)
        • 7.2.1.1. Reagents & Kits
        • 7.2.1.2. Instruments
        • 7.2.1.3. Software & Services
      • 7.2.2. Global Blood Screening by: Application (Value)
        • 7.2.2.1. Blood Bank
        • 7.2.2.2. Hospitals
      • 7.2.3. Global Blood Screening by: Technology (Value)
        • 7.2.3.1. Nucleic Acid Amplification Test (NAT)
        • 7.2.3.2. ELISA
        • 7.2.3.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
        • 7.2.3.4. Next-Generation Sequencing (NGS)
        • 7.2.3.5. Western Blotting
      • 7.2.4. Global Blood Screening Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Spain
          • 7.2.4.3.4. Italy
          • 7.2.4.3.5. Ireland
          • 7.2.4.3.6. United Kingdom
          • 7.2.4.3.7. Netherlands
          • 7.2.4.3.8. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Blood Screening (Price)
      • 7.3.1. Global Blood Screening by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blood Screening: by Type(USD Million)
  • Table 2. Blood Screening Reagents & Kits , by Region USD Million (2018-2023)
  • Table 3. Blood Screening Instruments , by Region USD Million (2018-2023)
  • Table 4. Blood Screening Software & Services , by Region USD Million (2018-2023)
  • Table 5. Blood Screening: by Application(USD Million)
  • Table 6. Blood Screening Blood Bank , by Region USD Million (2018-2023)
  • Table 7. Blood Screening Hospitals , by Region USD Million (2018-2023)
  • Table 8. Blood Screening: by Technology(USD Million)
  • Table 9. Blood Screening Nucleic Acid Amplification Test (NAT) , by Region USD Million (2018-2023)
  • Table 10. Blood Screening ELISA , by Region USD Million (2018-2023)
  • Table 11. Blood Screening Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) , by Region USD Million (2018-2023)
  • Table 12. Blood Screening Next-Generation Sequencing (NGS) , by Region USD Million (2018-2023)
  • Table 13. Blood Screening Western Blotting , by Region USD Million (2018-2023)
  • Table 14. South America Blood Screening, by Country USD Million (2018-2023)
  • Table 15. South America Blood Screening, by Type USD Million (2018-2023)
  • Table 16. South America Blood Screening, by Application USD Million (2018-2023)
  • Table 17. South America Blood Screening, by Technology USD Million (2018-2023)
  • Table 18. Brazil Blood Screening, by Type USD Million (2018-2023)
  • Table 19. Brazil Blood Screening, by Application USD Million (2018-2023)
  • Table 20. Brazil Blood Screening, by Technology USD Million (2018-2023)
  • Table 21. Argentina Blood Screening, by Type USD Million (2018-2023)
  • Table 22. Argentina Blood Screening, by Application USD Million (2018-2023)
  • Table 23. Argentina Blood Screening, by Technology USD Million (2018-2023)
  • Table 24. Rest of South America Blood Screening, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Blood Screening, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Blood Screening, by Technology USD Million (2018-2023)
  • Table 27. Asia Pacific Blood Screening, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Blood Screening, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Blood Screening, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Blood Screening, by Technology USD Million (2018-2023)
  • Table 31. China Blood Screening, by Type USD Million (2018-2023)
  • Table 32. China Blood Screening, by Application USD Million (2018-2023)
  • Table 33. China Blood Screening, by Technology USD Million (2018-2023)
  • Table 34. Japan Blood Screening, by Type USD Million (2018-2023)
  • Table 35. Japan Blood Screening, by Application USD Million (2018-2023)
  • Table 36. Japan Blood Screening, by Technology USD Million (2018-2023)
  • Table 37. India Blood Screening, by Type USD Million (2018-2023)
  • Table 38. India Blood Screening, by Application USD Million (2018-2023)
  • Table 39. India Blood Screening, by Technology USD Million (2018-2023)
  • Table 40. South Korea Blood Screening, by Type USD Million (2018-2023)
  • Table 41. South Korea Blood Screening, by Application USD Million (2018-2023)
  • Table 42. South Korea Blood Screening, by Technology USD Million (2018-2023)
  • Table 43. Taiwan Blood Screening, by Type USD Million (2018-2023)
  • Table 44. Taiwan Blood Screening, by Application USD Million (2018-2023)
  • Table 45. Taiwan Blood Screening, by Technology USD Million (2018-2023)
  • Table 46. Australia Blood Screening, by Type USD Million (2018-2023)
  • Table 47. Australia Blood Screening, by Application USD Million (2018-2023)
  • Table 48. Australia Blood Screening, by Technology USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Blood Screening, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Blood Screening, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Blood Screening, by Technology USD Million (2018-2023)
  • Table 52. Europe Blood Screening, by Country USD Million (2018-2023)
  • Table 53. Europe Blood Screening, by Type USD Million (2018-2023)
  • Table 54. Europe Blood Screening, by Application USD Million (2018-2023)
  • Table 55. Europe Blood Screening, by Technology USD Million (2018-2023)
  • Table 56. Germany Blood Screening, by Type USD Million (2018-2023)
  • Table 57. Germany Blood Screening, by Application USD Million (2018-2023)
  • Table 58. Germany Blood Screening, by Technology USD Million (2018-2023)
  • Table 59. France Blood Screening, by Type USD Million (2018-2023)
  • Table 60. France Blood Screening, by Application USD Million (2018-2023)
  • Table 61. France Blood Screening, by Technology USD Million (2018-2023)
  • Table 62. Spain Blood Screening, by Type USD Million (2018-2023)
  • Table 63. Spain Blood Screening, by Application USD Million (2018-2023)
  • Table 64. Spain Blood Screening, by Technology USD Million (2018-2023)
  • Table 65. Italy Blood Screening, by Type USD Million (2018-2023)
  • Table 66. Italy Blood Screening, by Application USD Million (2018-2023)
  • Table 67. Italy Blood Screening, by Technology USD Million (2018-2023)
  • Table 68. Ireland Blood Screening, by Type USD Million (2018-2023)
  • Table 69. Ireland Blood Screening, by Application USD Million (2018-2023)
  • Table 70. Ireland Blood Screening, by Technology USD Million (2018-2023)
  • Table 71. United Kingdom Blood Screening, by Type USD Million (2018-2023)
  • Table 72. United Kingdom Blood Screening, by Application USD Million (2018-2023)
  • Table 73. United Kingdom Blood Screening, by Technology USD Million (2018-2023)
  • Table 74. Netherlands Blood Screening, by Type USD Million (2018-2023)
  • Table 75. Netherlands Blood Screening, by Application USD Million (2018-2023)
  • Table 76. Netherlands Blood Screening, by Technology USD Million (2018-2023)
  • Table 77. Rest of Europe Blood Screening, by Type USD Million (2018-2023)
  • Table 78. Rest of Europe Blood Screening, by Application USD Million (2018-2023)
  • Table 79. Rest of Europe Blood Screening, by Technology USD Million (2018-2023)
  • Table 80. MEA Blood Screening, by Country USD Million (2018-2023)
  • Table 81. MEA Blood Screening, by Type USD Million (2018-2023)
  • Table 82. MEA Blood Screening, by Application USD Million (2018-2023)
  • Table 83. MEA Blood Screening, by Technology USD Million (2018-2023)
  • Table 84. Middle East Blood Screening, by Type USD Million (2018-2023)
  • Table 85. Middle East Blood Screening, by Application USD Million (2018-2023)
  • Table 86. Middle East Blood Screening, by Technology USD Million (2018-2023)
  • Table 87. Africa Blood Screening, by Type USD Million (2018-2023)
  • Table 88. Africa Blood Screening, by Application USD Million (2018-2023)
  • Table 89. Africa Blood Screening, by Technology USD Million (2018-2023)
  • Table 90. North America Blood Screening, by Country USD Million (2018-2023)
  • Table 91. North America Blood Screening, by Type USD Million (2018-2023)
  • Table 92. North America Blood Screening, by Application USD Million (2018-2023)
  • Table 93. North America Blood Screening, by Technology USD Million (2018-2023)
  • Table 94. United States Blood Screening, by Type USD Million (2018-2023)
  • Table 95. United States Blood Screening, by Application USD Million (2018-2023)
  • Table 96. United States Blood Screening, by Technology USD Million (2018-2023)
  • Table 97. Canada Blood Screening, by Type USD Million (2018-2023)
  • Table 98. Canada Blood Screening, by Application USD Million (2018-2023)
  • Table 99. Canada Blood Screening, by Technology USD Million (2018-2023)
  • Table 100. Mexico Blood Screening, by Type USD Million (2018-2023)
  • Table 101. Mexico Blood Screening, by Application USD Million (2018-2023)
  • Table 102. Mexico Blood Screening, by Technology USD Million (2018-2023)
  • Table 103. Blood Screening: by Type(USD/Units)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Blood Screening: by Type(USD Million)
  • Table 115. Blood Screening Reagents & Kits , by Region USD Million (2025-2030)
  • Table 116. Blood Screening Instruments , by Region USD Million (2025-2030)
  • Table 117. Blood Screening Software & Services , by Region USD Million (2025-2030)
  • Table 118. Blood Screening: by Application(USD Million)
  • Table 119. Blood Screening Blood Bank , by Region USD Million (2025-2030)
  • Table 120. Blood Screening Hospitals , by Region USD Million (2025-2030)
  • Table 121. Blood Screening: by Technology(USD Million)
  • Table 122. Blood Screening Nucleic Acid Amplification Test (NAT) , by Region USD Million (2025-2030)
  • Table 123. Blood Screening ELISA , by Region USD Million (2025-2030)
  • Table 124. Blood Screening Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) , by Region USD Million (2025-2030)
  • Table 125. Blood Screening Next-Generation Sequencing (NGS) , by Region USD Million (2025-2030)
  • Table 126. Blood Screening Western Blotting , by Region USD Million (2025-2030)
  • Table 127. South America Blood Screening, by Country USD Million (2025-2030)
  • Table 128. South America Blood Screening, by Type USD Million (2025-2030)
  • Table 129. South America Blood Screening, by Application USD Million (2025-2030)
  • Table 130. South America Blood Screening, by Technology USD Million (2025-2030)
  • Table 131. Brazil Blood Screening, by Type USD Million (2025-2030)
  • Table 132. Brazil Blood Screening, by Application USD Million (2025-2030)
  • Table 133. Brazil Blood Screening, by Technology USD Million (2025-2030)
  • Table 134. Argentina Blood Screening, by Type USD Million (2025-2030)
  • Table 135. Argentina Blood Screening, by Application USD Million (2025-2030)
  • Table 136. Argentina Blood Screening, by Technology USD Million (2025-2030)
  • Table 137. Rest of South America Blood Screening, by Type USD Million (2025-2030)
  • Table 138. Rest of South America Blood Screening, by Application USD Million (2025-2030)
  • Table 139. Rest of South America Blood Screening, by Technology USD Million (2025-2030)
  • Table 140. Asia Pacific Blood Screening, by Country USD Million (2025-2030)
  • Table 141. Asia Pacific Blood Screening, by Type USD Million (2025-2030)
  • Table 142. Asia Pacific Blood Screening, by Application USD Million (2025-2030)
  • Table 143. Asia Pacific Blood Screening, by Technology USD Million (2025-2030)
  • Table 144. China Blood Screening, by Type USD Million (2025-2030)
  • Table 145. China Blood Screening, by Application USD Million (2025-2030)
  • Table 146. China Blood Screening, by Technology USD Million (2025-2030)
  • Table 147. Japan Blood Screening, by Type USD Million (2025-2030)
  • Table 148. Japan Blood Screening, by Application USD Million (2025-2030)
  • Table 149. Japan Blood Screening, by Technology USD Million (2025-2030)
  • Table 150. India Blood Screening, by Type USD Million (2025-2030)
  • Table 151. India Blood Screening, by Application USD Million (2025-2030)
  • Table 152. India Blood Screening, by Technology USD Million (2025-2030)
  • Table 153. South Korea Blood Screening, by Type USD Million (2025-2030)
  • Table 154. South Korea Blood Screening, by Application USD Million (2025-2030)
  • Table 155. South Korea Blood Screening, by Technology USD Million (2025-2030)
  • Table 156. Taiwan Blood Screening, by Type USD Million (2025-2030)
  • Table 157. Taiwan Blood Screening, by Application USD Million (2025-2030)
  • Table 158. Taiwan Blood Screening, by Technology USD Million (2025-2030)
  • Table 159. Australia Blood Screening, by Type USD Million (2025-2030)
  • Table 160. Australia Blood Screening, by Application USD Million (2025-2030)
  • Table 161. Australia Blood Screening, by Technology USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Blood Screening, by Type USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Blood Screening, by Application USD Million (2025-2030)
  • Table 164. Rest of Asia-Pacific Blood Screening, by Technology USD Million (2025-2030)
  • Table 165. Europe Blood Screening, by Country USD Million (2025-2030)
  • Table 166. Europe Blood Screening, by Type USD Million (2025-2030)
  • Table 167. Europe Blood Screening, by Application USD Million (2025-2030)
  • Table 168. Europe Blood Screening, by Technology USD Million (2025-2030)
  • Table 169. Germany Blood Screening, by Type USD Million (2025-2030)
  • Table 170. Germany Blood Screening, by Application USD Million (2025-2030)
  • Table 171. Germany Blood Screening, by Technology USD Million (2025-2030)
  • Table 172. France Blood Screening, by Type USD Million (2025-2030)
  • Table 173. France Blood Screening, by Application USD Million (2025-2030)
  • Table 174. France Blood Screening, by Technology USD Million (2025-2030)
  • Table 175. Spain Blood Screening, by Type USD Million (2025-2030)
  • Table 176. Spain Blood Screening, by Application USD Million (2025-2030)
  • Table 177. Spain Blood Screening, by Technology USD Million (2025-2030)
  • Table 178. Italy Blood Screening, by Type USD Million (2025-2030)
  • Table 179. Italy Blood Screening, by Application USD Million (2025-2030)
  • Table 180. Italy Blood Screening, by Technology USD Million (2025-2030)
  • Table 181. Ireland Blood Screening, by Type USD Million (2025-2030)
  • Table 182. Ireland Blood Screening, by Application USD Million (2025-2030)
  • Table 183. Ireland Blood Screening, by Technology USD Million (2025-2030)
  • Table 184. United Kingdom Blood Screening, by Type USD Million (2025-2030)
  • Table 185. United Kingdom Blood Screening, by Application USD Million (2025-2030)
  • Table 186. United Kingdom Blood Screening, by Technology USD Million (2025-2030)
  • Table 187. Netherlands Blood Screening, by Type USD Million (2025-2030)
  • Table 188. Netherlands Blood Screening, by Application USD Million (2025-2030)
  • Table 189. Netherlands Blood Screening, by Technology USD Million (2025-2030)
  • Table 190. Rest of Europe Blood Screening, by Type USD Million (2025-2030)
  • Table 191. Rest of Europe Blood Screening, by Application USD Million (2025-2030)
  • Table 192. Rest of Europe Blood Screening, by Technology USD Million (2025-2030)
  • Table 193. MEA Blood Screening, by Country USD Million (2025-2030)
  • Table 194. MEA Blood Screening, by Type USD Million (2025-2030)
  • Table 195. MEA Blood Screening, by Application USD Million (2025-2030)
  • Table 196. MEA Blood Screening, by Technology USD Million (2025-2030)
  • Table 197. Middle East Blood Screening, by Type USD Million (2025-2030)
  • Table 198. Middle East Blood Screening, by Application USD Million (2025-2030)
  • Table 199. Middle East Blood Screening, by Technology USD Million (2025-2030)
  • Table 200. Africa Blood Screening, by Type USD Million (2025-2030)
  • Table 201. Africa Blood Screening, by Application USD Million (2025-2030)
  • Table 202. Africa Blood Screening, by Technology USD Million (2025-2030)
  • Table 203. North America Blood Screening, by Country USD Million (2025-2030)
  • Table 204. North America Blood Screening, by Type USD Million (2025-2030)
  • Table 205. North America Blood Screening, by Application USD Million (2025-2030)
  • Table 206. North America Blood Screening, by Technology USD Million (2025-2030)
  • Table 207. United States Blood Screening, by Type USD Million (2025-2030)
  • Table 208. United States Blood Screening, by Application USD Million (2025-2030)
  • Table 209. United States Blood Screening, by Technology USD Million (2025-2030)
  • Table 210. Canada Blood Screening, by Type USD Million (2025-2030)
  • Table 211. Canada Blood Screening, by Application USD Million (2025-2030)
  • Table 212. Canada Blood Screening, by Technology USD Million (2025-2030)
  • Table 213. Mexico Blood Screening, by Type USD Million (2025-2030)
  • Table 214. Mexico Blood Screening, by Application USD Million (2025-2030)
  • Table 215. Mexico Blood Screening, by Technology USD Million (2025-2030)
  • Table 216. Blood Screening: by Type(USD/Units)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blood Screening: by Type USD Million (2018-2023)
  • Figure 5. Global Blood Screening: by Application USD Million (2018-2023)
  • Figure 6. Global Blood Screening: by Technology USD Million (2018-2023)
  • Figure 7. South America Blood Screening Share (%), by Country
  • Figure 8. Asia Pacific Blood Screening Share (%), by Country
  • Figure 9. Europe Blood Screening Share (%), by Country
  • Figure 10. MEA Blood Screening Share (%), by Country
  • Figure 11. North America Blood Screening Share (%), by Country
  • Figure 12. Global Blood Screening: by Type USD/Units (2018-2023)
  • Figure 13. Global Blood Screening share by Players 2023 (%)
  • Figure 14. Global Blood Screening share by Players (Top 3) 2023(%)
  • Figure 15. Global Blood Screening share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 18. Grifols (Spain) Revenue: by Geography 2023
  • Figure 19. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 23. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 24. BioMérieux (France) Revenue: by Geography 2023
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 27. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Siemens Healthineers (Germany) Revenue: by Geography 2023
  • Figure 29. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Beckman Coulter, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Beckman Coulter, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Ortho Clinical Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Ortho Clinical Diagnostics, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 37. Global Blood Screening: by Type USD Million (2025-2030)
  • Figure 38. Global Blood Screening: by Application USD Million (2025-2030)
  • Figure 39. Global Blood Screening: by Technology USD Million (2025-2030)
  • Figure 40. South America Blood Screening Share (%), by Country
  • Figure 41. Asia Pacific Blood Screening Share (%), by Country
  • Figure 42. Europe Blood Screening Share (%), by Country
  • Figure 43. MEA Blood Screening Share (%), by Country
  • Figure 44. North America Blood Screening Share (%), by Country
  • Figure 45. Global Blood Screening: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Grifols (Spain)
  • Bio-Rad Laboratories, Inc. (United States)
  • Roche Diagnostics (Switzerland)
  • BioMérieux (France)
  • Abbott Laboratories (United States)
  • Siemens Healthineers (Germany)
  • Thermo Fisher Scientific, Inc. (United States)
  • Beckman Coulter, Inc. (United States)
  • Ortho Clinical Diagnostics, Inc. (United States)
  • Becton, Dickinson and Company (United States)
Additional players considered in the study are as follows:
Trinity Biotech (Ireland) , Luminex Corp (United States) , Alere Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 155 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Blood Screening Quantitative research analysis
Global Blood Screening Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Grifols (Spain), Bio-Rad Laboratories, Inc. (United States), Roche Diagnostics (Switzerland), BioMérieux (France), Abbott Laboratories (United States), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (United States), Beckman Coulter, Inc. (United States), Ortho Clinical Diagnostics, Inc. (United States) and Becton, Dickinson and Company (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Blood Screening Methods" is seen as one of major influencing trends for Blood Screening Market during projected period 2023-2030.
The Blood Screening market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Blood Screening Report?

Have a Query? Click Here

Other Related Reports

Tuberculosis Testing Comprehensive Study by Type (TB skin test (TST), TB blood tests, Others), Application (Hospitals, Clinics, Others), Disease (Active Tuberculosis, Latent Tuberculosis) Players and...
$ 3500
Human Papilloma Virus Testing Comprehensive Study by Type (Pap Smear Test, HPV DNA Test), Application (Diagnostic Centers, Hospitals, Clinic), Product Types (Consumables, Systems), Valence (Bivalent,...
$ 3650
IoT Healthcare Comprehensive Study by Application (Telemedicine, Work Flow Management, Connected Imaging, Medication Management), By Component (System and Software, Medical Devices, Services), By End...
$ 3650
Outbound Medical Tourism Services Comprehensive Study by Application (Adult, Children), Service Provider (Public, Private), Service (Medical VISA, Appointment Fixation, Treatment/Check-up Packages, C...
$ 3800
Leukapheresis Comprehensive Study by Type (Leukapheresis Disposables, Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)), Application (Research Institute, T...
$ 3750
Liver Function Tests Comprehensive Study by Type (Alanine Aminotransferase Test, Aspartate Aminotransferase Test, Alkaline Phosphatase Test, Gamma GT Test, Total Bilirubin, Albumin, Others), Applicat...
$ 3650